Anil Shinde

645 total citations
64 papers, 507 citations indexed

About

Anil Shinde is a scholar working on Molecular Biology, Pharmacology and Organic Chemistry. According to data from OpenAlex, Anil Shinde has authored 64 papers receiving a total of 507 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 21 papers in Pharmacology and 16 papers in Organic Chemistry. Recurrent topics in Anil Shinde's work include Cholinesterase and Neurodegenerative Diseases (18 papers), Receptor Mechanisms and Signaling (17 papers) and Sleep and Wakefulness Research (10 papers). Anil Shinde is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (18 papers), Receptor Mechanisms and Signaling (17 papers) and Sleep and Wakefulness Research (10 papers). Anil Shinde collaborates with scholars based in India, United States and United Kingdom. Anil Shinde's co-authors include Ramakrishna Nirogi, Pradeep Jayarajan, Vijay Benade, Gopinadh Bhyrapuneni, Ramkumar Subramanian, Vinod Goyal, Veera Raghava Chowdary Palacharla, Renny Abraham, P. K. Dubey and Nageswararao Muddana and has published in prestigious journals such as Neurology, Journal of Medicinal Chemistry and SLEEP.

In The Last Decade

Anil Shinde

60 papers receiving 489 citations

Peers

Countries citing papers authored by Anil Shinde

Since Specialization

Citations

This map shows the geographic impact of Anil Shinde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anil Shinde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anil Shinde more than expected).

Fields of papers citing papers by Anil Shinde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anil Shinde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anil Shinde. The network helps show where Anil Shinde may publish in the future.

Co-authorship network of co-authors of Anil Shinde

This figure shows the co-authorship network connecting the top 25 collaborators of Anil Shinde. A scholar is included among the top collaborators of Anil Shinde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anil Shinde. Anil Shinde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SUVN‐L3307032, A Positive Allosteric Modulator (PAM) at Muscarinic M4 Receptor for the Treatment of Neuropsychiatric Symptoms 2024 ·Alzheimer s & Dementia ·Anil Shinde, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Radhey Shyam, (unknown), Renny Abraham, Ramakrishna Nirogi	1
2	Samelisant (SUVN-G3031) - Topline Results from the Phase-2 Proof-of-Concept Double-blind, Placebo-controlled Study in Patients with Narcolepsy (P10-9.002) 2024 ·Neurology ·Ramakrishna Nirogi, Pradeep Jayarajan, Vijay Benade, Vinod Goyal, Anil Shinde, (unknown), (unknown), (unknown)	1
3	Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy 2024 ·Sleep Medicine ·Ramakrishna Nirogi, Anil Shinde, Vinod Goyal, (unknown), Vijay Benade, (unknown), (unknown), Ramkumar Subramanian, Veera Raghava Chowdary Palacharla, (unknown), Renny Abraham, (unknown), (unknown), Pradeep Jayarajan, (unknown), Richard Bogan	1
4	Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders 2023 ·Biomolecules ·Ramakrishna Nirogi, Pradeep Jayarajan, Anil Shinde, (unknown), (unknown), Vijay Benade, Vinod Goyal, Renny Abraham, (unknown), Jeffrey L. Cummings	31
5	0609 Samelisant, Histamine 3 Receptor Agonist for the Potential Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy 2023 ·SLEEP ·Ramakrishna Nirogi, (unknown), Pradeep Jayarajan, Vinod Goyal, (unknown), Anil Shinde, Vijay Benade	3
6	Masupirdine (SUVN‐502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type: Preliminary Efficacy and Phase‐3 Study Design 2023 ·Alzheimer s & Dementia ·Ramakrishna Nirogi, Renny Abraham, (unknown), (unknown), Vijay Benade, Anil Shinde, Mohammed Abdul Rasheed, (unknown), Vinod Goyal, Veera Raghava Chowdary Palacharla, Ramkumar Subramanian, Pradeep Jayarajan	0
7	Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects 2022 ·Clinical Drug Investigation ·Ramakrishna Nirogi, Vijay Benade, Vinod Goyal, (unknown), (unknown), Anil Shinde, (unknown), (unknown), (unknown), Veera Raghava Chowdary Palacharla	2
8	Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study 2022 ·Neurology and Therapy ·Ramakrishna Nirogi, Vinod Goyal, Vijay Benade, Ramkumar Subramanian, (unknown), (unknown), Anil Shinde, (unknown), Pradeep Jayarajan, (unknown), Jeffrey L. Cummings	5
9	Potential benefits of Masupirdine (SUVN-502) on Behavioral and Psychological symptoms in patients with moderate Alzheimer’s Disease (5090) 2020 ·Neurology ·Ramakrishna Nirogi, Anil Shinde, Pradeep Jayarajan, Vinod Goyal, (unknown), Ramkumar Subramanian, (unknown), (unknown), (unknown)	3
10	Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses 2020 ·Clinical Drug Investigation ·Ramakrishna Nirogi, Koteshwara Mudigonda, Gopinadh Bhyrapuneni, (unknown), Anil Shinde, Vinod Goyal, (unknown), (unknown), (unknown), (unknown), Veera Raghava Chowdary Palacharla	8
11	SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization 2018 ·Behavioural Pharmacology ·Ramakrishna Nirogi, Renny Abraham, Vijay Benade, (unknown), Pradeep Jayarajan, Gopinadh Bhyrapuneni, Nageswararao Muddana, (unknown), Ramkumar Subramanian, Anil Shinde, (unknown), (unknown)	30
12	Chronic treatment with a selective 5-HT6 receptor antagonist alters the behavioral and neurochemical effects of ethanol in young adult rats 2015 ·Behavioural Pharmacology ·Pradeep Jayarajan, Ramakrishna Nirogi, Anil Shinde, Vijay Benade, (unknown)	1
13	Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease 2015 ·European Journal of Medicinal Chemistry ·Ramakrishna Nirogi, (unknown), Anil Shinde, (unknown), (unknown), (unknown), (unknown), Gopinadh Bhyrapuneni, (unknown), Vijay Benade, Veera Raghava Chowdary Palacharla, Pradeep Jayarajan, Ramkumar Subramanian, Vinod Goyal	46
14	Benzamide derivatives and their constrained analogs as histamine H 3 receptor antagonists 2015 ·European Journal of Medicinal Chemistry ·Ramakrishna Nirogi, Anil Shinde, (unknown), (unknown), (unknown), (unknown), (unknown), Ramkumar Subramanian, (unknown), Gopinadh Bhyrapuneni, Renny Abraham	4
15	Diversity and abundance of spiders in mango fields of Latur district, Maharashtra state 2014 ·Journal of Entomological Research ·(unknown), Anil Shinde, (unknown), (unknown)	0
16	Role of glutamate and advantages of combining memantine with a 5HT6 ligand in a model of depression 2014 ·Pharmacological Reports ·Renny Abraham, Ramakrishna Nirogi, Anil Shinde	6
17	Effect of olanzapine on scopolamine induced deficits in differential reinforcement of low rate 72 s (DRL-72 s) schedule in rats: Involvement of the serotonergic receptors in restoring the deficits 2013 ·European Journal of Pharmacology ·Pradeep Jayarajan, Ramakrishna Nirogi, Anil Shinde	5
18	N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT6 receptor antagonists 2012 ·Bioorganic & Medicinal Chemistry Letters ·Ramakrishna Nirogi, (unknown), (unknown), Anil Shinde, (unknown), (unknown), (unknown), Pradeep Jayarajan, Vishwottam Kandikere, P. K. Dubey	12
19	Synthesis of novel (1-substituted benzenesulfonyl-1H-indol-5-yl)-(4-substituted piperazin-1-yl)-methanone derivatives as 5-HT6R ligands 2011 ·Der pharma chemica ·Ramakrishna Nirogi, (unknown), Anil Shinde, (unknown), (unknown), P. K. Dubey	0
20	Synthesis and pharmacological evaluation of aryl aminosulfonamide derivatives as potent 5-HT6 receptor antagonists 2010 ·Bioorganic & Medicinal Chemistry Letters ·Ramakrishna Nirogi, (unknown), (unknown), (unknown), (unknown), Anil Shinde, P. K. Dubey	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact